Enjoy complimentary customisation on priority with our Enterprise License!
The breast cancer therapeutics market size is forecast to increase by USD 15.64 billion at a CAGR of 8.4% between 2023 and 2028. The market is experiencing significant growth due to the rising prevalence of breast cancer, which is the most common cancer among women worldwide. According to the World Health Organization, there were approximately 2.3 million new cases of breast cancer in 2020. The market is also driven by the emergence of novel therapeutics, such as targeted therapies and immunotherapies, which offer more effective and personalized treatment options. However, the high cost of breast cancer treatment remains a major challenge for patients and healthcare systems, limiting access to these advanced therapies for many. Despite this, the market is expected to continue growing due to the increasing demand for effective treatments and the ongoing research and development efforts in the field.
Breast cancer is a significant health concern for females worldwide. The therapeutic approach to breast cancer involves various oncology drugs and therapeutics, including chemotherapy, radiation therapy, hormone therapy, targeted therapy, and immunotherapy. Chemotherapy utilizes medications to destroy rapidly dividing cells, affecting both cancerous and healthy tissues. Radiation therapy employs high-energy radiation to damage breast cancer cells. Hormone therapy targets the hormonal influences on breast cancer cells, while targeted therapy focuses on specific proteins or tissues. Immunotherapy stimulates the body's immune system to fight breast cancer cells. Breast cancer awareness campaigns and screening programs play a crucial role in early detection and reducing mortality rates.
Artificial intelligence is increasingly used to aid in breast cancer diagnoses, analyzing imaging data to identify potential tumors. Breast cancer can manifest as lumps, red patches, pain, swelling, bone pain, or lymph node involvement. Treatment may include surgical tumor removal, medications, and hormonal therapies. Symptoms such as pain, lumps, nipple changes, or breathing problems should be addressed promptly. Breast cancer can affect the milk ducts, milk-producing lobules, and surrounding tissues, potentially spreading to bones and lymph nodes.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The invasive breast cancers segment is estimated to witness significant growth during the forecast period. Breast cancer is a significant health concern for females worldwide, with invasive ductal carcinoma being the most prevalent type, accounting for approximately 80% of diagnoses. This form of cancer arises when malignant cells invade the milk ducts and milk-producing lobules, spreading to the surrounding tissues. Symptoms may include swelling, redness, pain, lumps, nipple discharge, and skin irritation. Risk factors include genetics, hormonal imbalances, environmental exposures, and lifestyle choices. Current therapeutic approaches for breast cancer involve a combination of chemotherapy, radiation therapy, hormone therapy, targeted therapy, and immunotherapy. Oncology drugs/therapeutics, such as proteins and hormonal therapies, play a crucial role in managing breast cancer.
Hormonal therapies, like tamoxifen and aromatase inhibitors, are effective for early-stage breast cancer and can reduce mortality rates and improve survival probabilities. Advancements in technology, such as artificial intelligence, are being explored to improve breast cancer diagnoses and treatment. For instance, targeted therapies like Herceptin, which targets the HER2 gene, have proven effective for females with positive HER2 receptors. Additionally, biosimilars are emerging as cost-effective alternatives to branded oncology drugs, offering affordability and accessibility to a larger patient population. Breast cancer can metastasize to various parts of the body, including bones, lymph nodes, and the brain. Symptoms of metastasis may include pain, swelling, breathing problems, and red patches. It is essential to raise awareness about breast cancer, emphasizing the importance of regular screening programs, early detection, and timely intervention.
Get a glance at the market share of various segments Request Free Sample
The invasive breast cancers segment was valued at USD 22.55 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The market in North America is experiencing significant growth due to various factors, including government support for treatments and increased hospital visits. In the US, the Centers for Medicare & Medicaid Services (CMS) offers reimbursements for breast cancer diagnosis and treatment, covering therapies such as Trastuzumab and IBRANCE. The US also introduced value-based care models to control therapeutic costs. Approximately 266,000 breast cancer cases are diagnosed annually in the US, with around 2,400 cases diagnosed in men. Risk factors, including obesity, alcohol intake, hormone problems during menopause, family history, and cancer type analysis, contribute to the high incidence rate. Patients can access breast cancer therapeutics through hospital pharmacies and online pharmacies, ensuring convenient access to essential treatments.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Rising prevalence of breast cancer is the key driver of the market. Breast cancer is the most frequently diagnosed cancer among women globally, making it a significant public health concern. According to the Centers for Disease Control and Prevention (CDC), approximately 278,000 new cases and 50,000 deaths related to breast cancer occur annually in the US. Early diagnosis through screening programs and increased breast cancer awareness have led to improved survival probabilities. However, despite these advancements, breast cancer remains a leading cause of morbidity and mortality. The therapeutic approach to breast cancer involves various oncology drugs and therapeutics, including chemotherapy, radiation therapy, hormone therapy, targeted therapy, and immunotherapy. Hormonal therapies, such as tamoxifen and aromatase inhibitors, are commonly used for hormone-receptor-positive breast cancers.
Herceptin, a monoclonal antibody, is an example of targeted therapy used for HER2-positive breast cancers. Breast cancer can manifest as lumps, red patches, pain, swelling, or even breathing problems. The disease can affect various tissues, including milk ducts, milk-producing lobules, and the nipple. In advanced stages, breast cancer can metastasize to the bones, lymph nodes, and brain. Advancements in oncology drugs and therapeutics, such as biosimilars and proteins, have led to improved treatment options and outcomes. Artificial intelligence and genetic testing are also being explored to aid in early diagnosis and personalized treatment plans. Despite these advancements, continued research, and awareness are essential to reduce breast cancer mortality and improve survival probabilities for females.
Emerging novel therapeutics is the upcoming trend in the market. Breast cancer therapeutics encompass a range of approaches and drugs, including chemotherapy, radiation therapy, hormone therapy, targeted therapy, and immunotherapy. These oncology drugs/therapeutics aim to combat breast cancer by various mechanisms, such as inhibiting proteins in breast cancer cells, stimulating the immune system, and obstructing the growth of blood vessels supplying nutrients to tumors. Hormonal therapies, which target hormonal receptors in breast tissue, are commonly used for early-stage breast cancer, reducing morbidity and mortality. Newer therapeutic approaches include PARP inhibitors and CDK inhibitors, which have shown promise in clinical trials for triple-negative breast cancers. For instance, the combination therapy ZEJULA and KEYTRUDA, a PARP inhibitor and an anti-PD-1 immunotherapy, respectively, has demonstrated positive response rates in Phase I/II clinical trials.
Additionally, PD-L1 inhibitors like Atezolizumab, a humanized monoclonal antibody, are being developed to target the PD-L1 protein that contributes to tumor growth and survival. Breast cancer awareness campaigns and screening programs play a crucial role in early detection, which significantly improves survival probabilities. Despite advancements in breast cancer therapeutics, challenges remain, such as the development of brain metastasis, resistance to hormonal therapies, and the high cost of innovative treatments. The emergence of artificial intelligence and gene-targeted therapies offers potential solutions to these challenges. Breast cancer can manifest as lumps, red patches, pain, swelling, or breathing problems. It affects females and involves the milk ducts and milk-producing lobules, with tumors potentially spreading to bones, lymph nodes, and other organs.
Hormonal therapies, such as Herceptin, can be administered to females with positive HER2 receptors. Biosimilars, which are similar to branded biologic drugs but with minor differences, are also being developed to make these treatments more accessible and affordable.
The high cost of treatment is a key challenge affecting the market growth. Breast cancer is a significant health concern for females worldwide, with increasing incidences leading to a high demand for effective therapeutic approaches. The therapeutic landscape for breast cancer includes various treatments such as chemotherapy, radiation therapy, hormone therapy, targeted therapy, and immunotherapy. Oncology drugs/therapeutics, including proteins, play a crucial role in managing breast cancer at various stages. Early detection through breast cancer awareness programs and screening initiatives contribute to improved survival probabilities and reduced morbidity. However, the high costs of these therapeutics pose a challenge, with expensive treatments such as Avastin (bevacizumab) and KADCYLA, which cost around USD 50,000 and USD 115,974 per treatment episode or individual, respectively.
The emergence of targeted therapies, such as monoclonal antibodies, offers potential benefits but adds to the financial burden. HER2-positive breast cancer cells, which form tumors in milk ducts and milk-producing lobules, can metastasize to the brain, bones, lymph nodes, and other organs, leading to symptoms like red patches, pain, swelling, lumps, nipple discharge, and breathing problems. Hormonal therapies, such as Herceptin, are effective in managing hormone-sensitive breast cancer, while biosimilars offer cost-effective alternatives. Gene mutations, particularly those involving the HER2 receptor, play a significant role in breast cancer development and progression.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc. - The company offers breast cancer therapeutics such as Ibrutinib which is an anti-neoplastic agent. It is formulated as hard gelatin capsules, tablets, film coated tablets and suspension for oral route of administration.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Breast cancer is a major health concern for females worldwide. The therapeutic approach to breast cancer involves various methods such as chemotherapy, radiation therapy, hormone therapy, targeted therapy, and immunotherapy. Oncology drugs/therapeutics play a crucial role in treating breast cancer. These drugs include proteins that target specific breast cancer cells, such as those found in milk ducts and milk-producing lobules. Early detection through breast cancer awareness programs and screening programs is essential for improving survival probabilities and reducing morbidity. Breast cancer can present with various symptoms, including lumps, red patches, pain, swelling, lymph node involvement, and even brain metastasis.
Further, hormonal therapy, such as hormonal therapies for positive her2 receptor breast cancers like Herceptin, is an effective treatment for many patients. The use of artificial intelligence in breast cancer diagnoses is also gaining popularity, helping to improve accuracy and reduce false positives. Breast cancer mortality rates continue to decline due to advancements in therapies. However, the development of biosimilars for oncology drugs is expected to increase competition and affordability in the market. Breast cancer can spread to bones, causing pain and breathing problems. Genes play a significant role in the development of breast cancer, with certain genes increasing the risk for the disease.
Market Scope |
|
Report Coverage |
Details |
Page number |
168 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 8.4% |
Market Growth 2024-2028 |
USD 15.64 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
7.49 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 46% |
Key countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Clovis Oncology Inc., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly and Co., Exelixis Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Novartis AG, PerkinElmer Inc, Pfizer Inc., Puma Biotechnology Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Disease Type
7 Market Segmentation by Therapy
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.